<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="4fa51e7c-c82d-4fbb-bb58-c2664eebd262"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use EOVISTÂ® safely and effectively.  See full prescribing information for EOVIST.<br/>
      <content styleCode="bold">EOVIST (gadoxetate disodium) injection, for intravenous use</content>
      <br/>Initial U.S. Approval: 2008</title>
   <effectiveTime value="20250305"/>
   <setId root="6218b1e1-cbc3-4c14-bec7-528ac163a561"/>
   <versionNumber value="22"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005436809" root="1.3.6.1.4.1.519.1"/>
            <name>Bayer HealthCare Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="315097875" root="1.3.6.1.4.1.519.1"/>
                        <name>Bayer AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="825078165" root="1.3.6.1.4.1.519.1"/>
                        <name>QUALITY PACKAGING SPECIALISTS INTERNATIONAL LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="314398484" root="1.3.6.1.4.1.519.1"/>
                        <name>Bayer AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="313113144" root="1.3.6.1.4.1.519.1"/>
                        <name>Dynamit Nobel GmbH ES</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="216df7eb-1fb3-4ef7-9975-24ae54782c23"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20150327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50419-320" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>EOVIST</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Gadoxetate Disodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="181.43"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="HOY74VZE0M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GADOXETATE DISODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AZV954TZ9N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GADOLINIUM CATION (3+)</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="023C2WHX2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TROMETHAMINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50419-320-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20080703"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50419-320-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20080703"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50419-320-75" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20080703"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022090" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080703"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_f7f5efa8-6bca-4cd8-83cc-a779a6c166ba">
               <id root="46daed75-2ec7-45bc-a299-589528ac2779"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF) </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Risk Associated with Intrathecal Use</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. EOVIST is not approved for intrathecal use <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_33022c96-c0bd-4ffb-8d5a-427f8fc62377">5.1</linkHtml>)]</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Nephrogenic Systemic Fibrosis</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of EOVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The risk for NSF appears highest among patients with:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>Â </caption>
                        <list listType="unordered">
                           <item>
                              <caption>o</caption>
                              <content styleCode="bold">Chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>), or</content>
                           </item>
                           <item>
                              <caption>o</caption>
                              <content styleCode="bold">Acute kidney injury.</content>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age &gt; 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For patients at highest risk for NSF, do not exceed the recommended EOVIST dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration <content styleCode="italics">[see Warnings and Precautions (</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.2</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">)].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="_Toc193709088">WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS  </paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="bold">Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. EOVIST is not approved for intrathecal use (<linkHtml href="#ID_33022c96-c0bd-4ffb-8d5a-427f8fc62377">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Avoid use of EOVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.</content>
                           </item>
                           <item>
                              <caption>Â </caption>
                              <content styleCode="bold">The risk for NSF appears highest among patients with:</content>
                              <list listType="ordered">
                                 <item>
                                    <caption>o</caption>
                                    <content styleCode="bold">Chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>), or</content>
                                 </item>
                                 <item>
                                    <caption>o</caption>
                                    <content styleCode="bold">Acute kidney injury.</content>
                                 </item>
                              </list>
                           </item>
                           <item>
                              <caption>Â </caption>
                              <content styleCode="bold">Screen patients for acute kidney injury and other conditions that may reduce renal function.</content>
                           </item>
                           <item>
                              <caption>Â </caption>
                              <content styleCode="bold">For patients at risk for chronically reduced renal function (for example, age &gt;60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing (</content>
                              <content styleCode="bold">
                                 <linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.2</linkHtml>
                              </content>
                              <content styleCode="bold">).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_a79070de-e10f-4ce0-8963-ca6b0c00f3e9">
               <id root="6824c064-09b7-4b67-9839-6f25d157f420"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>EOVIST is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.</paragraph>
               </text>
               <effectiveTime value="20150327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>EOVIST is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_049b9a73-c95b-4c0c-9933-11a627f38010">
               <id root="f4394ee9-8534-4406-ae99-100027333559"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>2.1	Recommended Dose</title>
               <text>
                  <paragraph>The recommended dose of EOVIST is 0.1 mL/kg body weight (0.025 mmol/kg body weight).  </paragraph>
               </text>
               <effectiveTime value="20150327"/>
            </section>
         </component>
         <component>
            <section ID="ID_6d248351-648e-45c0-97c0-117e3466d861">
               <id root="b4c4e555-aae7-4ece-ae06-a68065246d32"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Recommended dose is 0.1 mL/kg body weight (<linkHtml href="#ID_049b9a73-c95b-4c0c-9933-11a627f38010">2.1</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Administer as an intravenous injection at a recommended rate of 1 mL to 2 mL per second (<linkHtml href="#ID_83143394-a3e7-4937-a25e-23dddf76133a">2.2</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Follow injection with a normal saline flush (<linkHtml href="#ID_83143394-a3e7-4937-a25e-23dddf76133a">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_83143394-a3e7-4937-a25e-23dddf76133a">
                     <id root="ebb9ae58-cb90-4af2-b2a3-8df359c5ae7c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Drug Handling and Administration</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Use sterile technique when preparing and administering EOVIST</item>
                           <item>
                              <caption>â¢</caption>Visually inspect EOVIST, supplied in a single-dose container (vial), for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or if particulate matter is present</item>
                           <item>
                              <caption>â¢</caption>Use EOVIST immediately after obtaining appropriate dose from vial. The rubber stopper should never be pierced more than once. Discard any unused portion of an EOVIST vial</item>
                           <item>
                              <caption>â¢</caption>Administer EOVIST undiluted as an intravenous injection at a recommended rate of 1 mL to 2 mL per second.</item>
                           <item>
                              <caption>â¢</caption>Do not mix EOVIST with other medications and do not administer EOVIST in the same intravenous line simultaneously with other medications</item>
                           <item>
                              <caption>â¢</caption>Flush the intravenous cannula with a normal saline solution after EOVIST injection</item>
                           <item>
                              <caption>â¢</caption>Imaging can commence immediately following EOVIST administration</item>
                        </list>
                     </text>
                     <effectiveTime value="20211231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d278da5b-1e14-442c-9306-cdd48ecc0a19">
                     <id root="d1c4ffe4-9d50-4fdb-9b1d-a95c11b1b030"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Imaging</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Liver lesions are detected and characterized with pre-contrast MRI and EOVIST MRI obtained during dynamic and hepatocyte imaging phases. Perform a pre-contrast MRI, inject EOVIST and begin dynamic imaging approximately 15â25 seconds after completion of the injection. Dynamic imaging consists of the arterial, the porto-venous (approximately 60 seconds post-injection), and the blood equilibrium (approximately 120 seconds) phases. </item>
                           <item>
                              <caption>â¢</caption>Begin the hepatocyte imaging phase approximately 20 minutes post-injection. Hepatocyte phase imaging may be performed up to 120 minutes post-injection.</item>
                           <item>
                              <caption>â¢</caption>Elevated intrinsic levels of bilirubin (&gt;3 mg/dL) or ferritin can reduce the hepatic contrast effect of EOVIST. Perform MR imaging no later than 60 minutes following EOVIST administration to patients with these laboratory abnormalities, including patients who have elevated ferritin levels due to hemodialysis <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.7</linkHtml>
                              </content>
                              <content styleCode="italics">) and Use in Specific Populations (<linkHtml href="#ID_27fed83f-d4d1-4cb3-b841-1320ba0245a1">8.6</linkHtml>, <linkHtml href="#ID_35d91d30-16f2-4827-8782-8ad3693d268f">8.7</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>â¢</caption>Lesions with no or minimal hepatocyte function (cysts, metastases, and the majority of hepatocellular carcinomas) generally will not accumulate EOVIST. Well-differentiated hepatocellular carcinoma may contain functioning hepatocytes and can show some enhancement in the hepatocyte imaging phase. Additional clinical information is therefore needed to support a diagnosis of hepatocellular carcinoma. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3809cc02-18f3-4099-8c81-fbce88834211">
               <id root="a10961ec-7f76-421f-af81-a27ca0ce454f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>EOVIST is a sterile, clear, and colorless to pale yellow solution for injection containing 181.43 mg gadoxetate disodium per mL (equivalent to 0.25 mmol gadoxetate disodium per mL) supplied in single-dose containers (vials).</paragraph>
               </text>
               <effectiveTime value="20150327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 181.43 mg/mL in single-dose containers (vials) (<linkHtml href="#ID_3809cc02-18f3-4099-8c81-fbce88834211">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_aef2a2d9-f83d-4272-b54c-08c05db9b985">
               <id root="d3a3c81e-fd9d-42d0-8347-db7d2da8362f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4	CONTRAINDICATIONS</title>
               <text>
                  <paragraph>EOVIST is contraindicated in patients with history of severe hypersensitivity reactions to EOVIST <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of severe hypersensitivity reaction to EOVIST (<linkHtml href="#ID_aef2a2d9-f83d-4272-b54c-08c05db9b985">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_89426b80-6515-4a14-b997-1d3cabe80ea8">
               <id root="b06c1df8-e8fd-4d32-aad5-ecc143667e98"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Hypersensitivity Reactions: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.  Monitor patients closely for need of emergency cardiorespiratory support (<linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.3</linkHtml>)</item>
                           <item>
                              <caption>â¢</caption>Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. (<linkHtml href="#ID_89426b80-6515-4a14-b997-1d3cabe80ea8">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_33022c96-c0bd-4ffb-8d5a-427f8fc62377">
                     <id root="024a5615-576f-4f17-bf02-af70836d8049"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Risk Associated with Intrathecal Use </title>
                     <text>
                        <paragraph>Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of EOVIST have not been established with intrathecal use. EOVIST is not approved for intrathecal use <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_83143394-a3e7-4937-a25e-23dddf76133a">2.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c5cc0f7b-918c-46be-9524-d974c2c13804">
                     <id root="8363232f-4ab6-4fa1-b1c6-919a148a97d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Nephrogenic Systemic Fibrosis (NSF)</title>
                     <text>
                        <paragraph>GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of EOVIST among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m<sup>2</sup>) as well as patients with acute kidney injury. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30 to 59 mL/min/1.73m<sup>2</sup>) and little, if any, for patients with chronic, mild kidney disease (GFR 60 to 89 mL/min/1.73m<sup>2</sup>). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Report any diagnosis of NSF following EOVIST administration to Bayer HealthCare (1-888-842-2937) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
                        <paragraph>Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (for example, age &gt; 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing.</paragraph>
                        <paragraph>Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administrated to a patient. For patients at highest risk for NSF, do not exceed the recommended EOVIST dose and allow a sufficient period of time for elimination of the drug prior to any re-administration. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA in order to enhance the contrast agentâs elimination <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_27fed83f-d4d1-4cb3-b841-1320ba0245a1">8.6</linkHtml>) </content>and<content styleCode="italics"> Clinical Pharmacology (<linkHtml href="#ID_82356868-ed0d-4369-aacc-85aefb7bd6bb">12.3</linkHtml>)].</content> The usefulness of hemodialysis in the prevention of NSF is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_69695609-5c2d-44ad-9be3-88ee6bea7a9b">
                     <id root="23e8cd81-758b-4633-980c-10d1663b1d40"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_30b99294-abde-4813-8fa9-49ace98be36b">6</linkHtml>)]</content>.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Before EOVIST administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to EOVIST.</item>
                           <item>
                              <caption>â¢</caption>Administer EOVIST only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.</item>
                        </list>
                        <paragraph>Most hypersensitivity reactions to EOVIST have occurred within half an hour after administration. Delayed reactions can occur up to several days after EOVIST administration. Observe patients for signs and symptoms of hypersensitivity reactions during and following EOVIST administration. </paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_78962487-2844-444d-b407-579a305f45b4">
                     <id root="4b703ffa-2400-4bf1-8c0b-1a6010ca063d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Gadolinium Retention </title>
                     <text>
                        <paragraph>Gadolinium is retained for months or years in several organs. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (for example, brain, skin, kidney, liver, and spleen). The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, gadolinium retention varies among the linear agents with Omniscan (gadodiamide) and Optimark (gadoversetamide) causing greater retention than other linear agents [Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine),MultiHance (gadobenate dimeglumine)]. Retention is lowest and similar among the macrocyclic GBCAs [Dotarem (gadoterate meglumine), Gadavist (gadobutrol), ProHance (gadoteridol)]. </paragraph>
                        <paragraph>Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#ID_c5cc0f7b-918c-46be-9524-d974c2c13804">5.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>. There are rare reports of pathologic skin changes in patients with normal renal function. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention <content styleCode="italics">[see Adverse Reactions (<content styleCode="underline">
                                 <linkHtml href="#_6.2_Postmarketing_Experience">6.2</linkHtml>
                              </content>)]</content>.</paragraph>
                        <paragraph>While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing a GBCA for these patients. Minimize repetitive GBCA imaging studies particularly closely spaced studies, when possible.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_01cef409-0ab2-4229-aee5-c256babaf2bc">
                     <id root="863fb8fc-6d64-42a4-a846-0b3710898aca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Acute Kidney Injury</title>
                     <text>
                        <paragraph>In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs. The risk of acute kidney injury might be lower with EOVIST due to its dual excretory pathways. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c1395be2-dc5f-4bad-8cdf-34719092ee6b">
                     <id root="54066cdd-d3bc-4838-8a02-3a39cd3976bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Extravasation and Injection Site Reactions</title>
                     <text>
                        <paragraph>Ensure catheter and venous patency before the injection of EOVIST. Extravasation into tissues during EOVIST administration may result in local tissue reactions. Strictly avoid intramuscular administration of EOVIST because it may cause myocyte necrosis and inflammation <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#ID_324c584d-eb0e-48dc-b609-13454eeef7ec">13.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3deed9af-6c1f-4c4a-a37b-b40a0ee634e8">
                     <id root="2366bfba-5552-459c-86e4-547522405924"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Interference with Laboratory Tests</title>
                     <text>
                        <paragraph>Serum iron determination using complexometric methods (for example, ferrocene complexation method) may result in falsely high or low values for up to 24 hours after the examination with EOVIST because of the caloxetate trisodium excipients <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_b55b90f1-c423-453d-a478-01232a7540a0">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_48d2cef3-93e1-4a07-a5dc-c004380265c7">
                     <id root="7112d8f3-2b49-43bb-badc-a40f8c919a85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Interference with Visualization of Liver Lesions</title>
                     <text>
                        <paragraph>Severe renal or hepatic failure may impair EOVIST imaging performance. In patients with end-stage renal failure, hepatic contrast was markedly reduced and was attributed to elevated serum ferritin levels. In patients with abnormally high (&gt;3Â mg/dL) serum bilirubin, reduced hepatic contrast was observed. If EOVIST is used in these patients, complete MRI no later than 60 minutes after EOVIST administration and use a paired non-contrast and contrast MRI set for diagnosis.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_30b99294-abde-4813-8fa9-49ace98be36b">
               <id root="8c2fd9cf-2175-40a9-a5b0-70f820ee6111"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Nephrogenic systemic fibrosis (NSF) <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_c5cc0f7b-918c-46be-9524-d974c2c13804">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>â¢</caption>Hypersensitivity reactions <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_aef2a2d9-f83d-4272-b54c-08c05db9b985">4</linkHtml>) and Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_69695609-5c2d-44ad-9be3-88ee6bea7a9b">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>â¢</caption>Gadolinium Retention<content styleCode="italics"> [see Warnings and Precautions (5.4)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence â¥ 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (<linkHtml href="#ID_30b99294-abde-4813-8fa9-49ace98be36b">6</linkHtml>)</paragraph>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_b55b90f1-c423-453d-a478-01232a7540a0">
                     <id root="e8c54f2e-6212-47f3-9522-aada53166d97"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The adverse reactions described in this section reflect EOVIST exposure in 1,989 subjects with the majority (1,581 subjects) receiving the recommended dose. Overall, 59% of the subjects were men and the ethnic distribution was 64% Caucasian, 22% Asian, 3% Hispanic, 2% Black, and 0.5% of subjects consisted of other ethnic groups. The average age was 57 years (age range from 19 to 84 years).</paragraph>
                        <paragraph>Overall, 4% of subjects reported one or more adverse reactions following EOVIST administration. The most frequent (â¥Â 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain. Adverse reactions were predominantly of mild to moderate severity.</paragraph>
                        <paragraph>Table 1 lists adverse reactions that occurred in â¥ 0.1% of subjects treated with EOVIST.</paragraph>
                        <paragraph/>
                        <table width="100%">
                           <caption>Table 1 Adverse Reactions</caption>
                           <col width="41%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Rate (%)<br/>n = 1581</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Feeling hot</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Back pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Blood pressure increased </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Injection site reactions (pain, burning, coldness, extravasation, irritation)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Dysgeusia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Paresthesia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Flushing</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Parosmia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pruritus (generalized, eye)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Respiratory disorders (dyspnea, respiratory distress)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Chest pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Vertigo</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Dry mouth</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Chills</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Feeling abnormal</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Adverse reactions that occurred with a frequency of &lt; 0.1% in subjects who received EOVIST include: tremor, akathisia, bundle branch block, palpitation, oral discomfort, salivary hypersecretion, maculopapular rash, hyperhidrosis, discomfort, and malaise.</paragraph>
                        <paragraph>Elevation of serum iron values and serum bilirubin laboratory values were reported in less than 1% of patients after administration of EOVIST.  The values did not exceed more than 3 times the baseline values and returned to baseline within 1 to 4 days.</paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ee7298d1-06ec-4ce2-996e-71844bab1adc">
                     <id root="01458239-aa9c-46bb-8471-60e89aa05845"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been identified during the postmarketing use of EOVIST or other GBCAs. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>Hypersensitivity reactions (anaphylactic shock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) </item>
                           <item>
                              <caption>â¢</caption>Respiratory, Thoracic, and Mediastinal Disorders: Acute respiratory distress syndrome, pulmonary edema</item>
                           <item>
                              <caption>â¢</caption>Tachycardia</item>
                           <item>
                              <caption>â¢</caption>Restlessness  </item>
                           <item>
                              <caption>â¢</caption>General Disorders and Administration Site Conditions:  Adverse reactions with variable onset and duration have been reported after GBCA administration. These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems<content styleCode="italics">.</content>
                           </item>
                           <item>
                              <caption>â¢</caption>Skin: Gadolinium associated plaques</item>
                           <item>
                              <caption>â¢</caption>Gastrointestinal Disorders: Acute pancreatitis with onset within 48 hours after GBCA administration</item>
                        </list>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_46e2e1d8-4775-43ee-9cfc-41bbd094dd5d">
               <id root="31541fc7-36d5-4e71-b85f-ff71b6bf7be5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250305"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy: Use only if imaging is essential during pregnancy and cannot be delayed. (</content>
                           <linkHtml href="#ID_1fff6def-0eeb-4721-89e1-40bc84243f36">8.1</linkHtml>
                           <content styleCode="underline">)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1fff6def-0eeb-4721-89e1-40bc84243f36">
                     <id root="18d4fe18-c887-4c41-8230-5f6956a494be"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250305"/>
                     <component>
                        <section ID="ID_31ba1002-2598-4394-a33d-4350a950cc2b">
                           <id root="a0dcce30-4eed-4957-814f-a3a9d4c7e65c"/>
                           <code code="69759-9" codeSystem="2.16.840.1.113883.6.1" displayName="RISKS"/>
                           <title>Risk Summary </title>
                           <text>
                              <paragraph>GBCAs have been shown to cross the human placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive <content styleCode="italics">(see Data). </content>In animal</paragraph>
                              <paragraph>reproduction studies, no teratogenicity was observed with repeated daily intravenous administration of gadoxetate disodium to rats during organogenesis at doses up to 32 times the recommended single human dose; however, an increase in preimplantation loss was noted at doses 3.2 times the single human dose. Post implantation loss was observed with repeated daily intravenous administration of gadoxetate disodium to rabbits on gestation days 6 through 18 at doses 26 times the recommended single human dose <content styleCode="italics">(see Data)</content>.  Because of the potential risks of gadolinium to the fetus, use EOVIST only if imaging is essential during pregnancy and cannot be delayed.</paragraph>
                              <paragraph>The background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.</paragraph>
                           </text>
                           <effectiveTime value="20150327"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_ad301eb2-988b-465b-993f-7ec9bff3f128">
                           <id root="17e1872e-3cab-44c6-ae4d-2496622be46b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Data </title>
                           <effectiveTime value="20250305"/>
                           <component>
                              <section ID="ID_cb110a07-192c-4ec4-98a1-c0cc1366f26b">
                                 <id root="0d089d92-e7d8-43c4-bbf3-8f6e491835b4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Human Data </title>
                                 <text>
                                    <paragraph>Contrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration.</paragraph>
                                    <paragraph>Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250305"/>
                                 <component>
                                    <section ID="ID_e1ba6e0a-2a9e-4222-88a3-c472a7d47945">
                                       <id root="5b25d944-a1cf-4e5d-a1d3-b9f31c4bc5c7"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <title>Gadolinium Retention </title>
                                       <text>
                                          <paragraph>GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months.  GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age.</paragraph>
                                       </text>
                                       <effectiveTime value="20250305"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="ID_c1375986-ffd4-43b0-a334-c4773949af42">
                                       <id root="a0c5680b-8ef2-4a8f-aaf3-b51962d9289a"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <title>Reproductive Toxicology </title>
                                       <text>
                                          <paragraph>Animal reproductive and developmental toxicity studies were done in rats and rabbits. Gadoxetate disodium was not teratogenic when given intravenously during organogenesis to pregnant rats at doses up to 32 times the recommended single human dose (mmol/m<sup>2</sup> basis). However, an increase in preimplantation loss was noted at 3.2 times the human dose (mmol/m<sup>2</sup> basis).  Compared to untreated controls, rates of postimplantation loss and absorption increased and litter size decreased when pregnant rabbits received gadoxetate disodium at doses 26 times the recommended human single dose (mmol/m<sup>2</sup> basis).  This occurred without evidence of maternal toxicity. Because pregnant animals received repeated daily doses of gadoxetate disodium, their overall exposure was significantly higher than that achieved with the standard single dose administered to humans.</paragraph>
                                       </text>
                                       <effectiveTime value="20150327"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_cd05b397-14d4-46a6-9ee7-24eb6245faca">
                     <id root="6ebde932-b61a-4d85-940d-444acba7f42b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of gadoxetate disodium in human milk, the effects of the drug in a breastfed infant, or the effects of the drug on milk production.  However, published lactation data on other GBCAs report that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk and there is limited GBCA gastrointestinal absorption in the breastfed infant.  In rat lactation studies with [<sup>153</sup>Gd] gadoxetate disodium, less than 0.5% of the total administered radioactivity was transferred to the nursing pup.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for up to 10 hours after EOVIST administration in order to minimize exposure to a breastfed infant.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In lactating rats given 0.1Â mmol/kg [<sup>153</sup>Gd] gadoxetate disodium, less than 0.5% of the total administered radioactivity was transferred to the neonates via maternal milk, mostly within 2Â hours. </paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_70e825cb-a2f3-459b-8dc6-52a7815efeb7">
                     <id root="36a33ee2-9bd8-440c-888d-b4007a21f72b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>Adequate and well-controlled studies of EOVIST in pediatric patients have not been conducted.  An observational study with EOVIST was performed in 52 patients (aged &gt; 2 months and &lt; 18 years) referred for evaluation of suspected or known focal liver lesions. EOVIST improved border delineation and increased contrast of the primary lesion in the majority of patients when compared to non-contrast images.  No safety issues were identified.</paragraph>
                        <paragraph>No dose adjustment according to age is necessary in pediatric patients<content styleCode="italics">.  </content>The safety and effectiveness of EOVIST have not been established in premature infants.</paragraph>
                        <paragraph>
                           <content styleCode="italics">NSF Risk</content>
                        </paragraph>
                        <paragraph>No case of NSF associated with EOVIST or any other GBCA has been identified in pediatric patients ages 6 years and younger.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Juvenile Animal Data</content>
                        </paragraph>
                        <paragraph>Single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants.</paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_93997f81-d47a-4534-8b86-834337e67b66">
                     <id root="c74f7e11-e7eb-4c4f-b573-f54ab414847e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>In clinical studies of EOVIST, 674 (34%) patients were 65 years of age and over, while 20 (1%) were 80 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, use of EOVIST in an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>In a clinical pharmacology study, slight to moderate differences in pharmacokinetic parameters of gadoxetate disodium (increased AUC and terminal half-life, decreased total clearance) were found in a group of geriatric volunteers in comparison to non-geriatric volunteers. No clinically relevant differences in liver contrast enhancement were found. </paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_27fed83f-d4d1-4cb3-b841-1320ba0245a1">
                     <id root="6eb71371-480e-463c-931e-39e103ac1110"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>In a clinical pharmacology study in a group of patients with moderate renal impairment, a moderate increase in AUC and terminal half-life was observed in comparison to healthy volunteers with normal renal function. Hepatic contrast did not differ among the groups.</paragraph>
                        <paragraph>End-stage renal failure may impair EOVIST imaging performance<content styleCode="italics"> [see Warnings and Precautions (5.7)]. </content>In a study of patients with end-stage renal failure, the terminal half-life was prolonged about 12-fold and the AUC was increased about 6-fold. Hepatic contrast was markedly reduced in these patients, which was attributed to significantly elevated serum ferritin levels<content styleCode="italics"> [see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_c5cc0f7b-918c-46be-9524-d974c2c13804">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.<content styleCode="italics"/>Approximately 30% of the injected dose was removed by dialysis in a single 3-hour dialysis session, which started one hour after an EOVIST dose. EOVIST was almost completely eliminated via dialysis and biliary excretion within the observation period of 6 days, predominantly within the first 3 days.</paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_35d91d30-16f2-4827-8782-8ad3693d268f">
                     <id root="43b5d56a-fa82-4861-8f5b-667d9f1de405"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7	Hepatic Impairment</title>
                     <text>
                        <paragraph>In a clinical pharmacology study in groups of patients with mild or moderate hepatic impairment, a slight to moderate increase in plasma AUC, half-life and urinary excretion, as well as decrease in hepatobiliary excretion was observed in comparison to healthy subjects with normal liver function.  Hepatic contrast signal did not differ among the groups.</paragraph>
                        <paragraph>Severe hepatic impairment may impair EOVIST imaging performance <content styleCode="italics">[see Warnings and Precautions (5.7)]</content>.<content styleCode="italics"/>In patients with severe hepatic impairment, especially in patients with abnormally high (&gt;Â 3Â mg/dL) serum bilirubin levels, the AUC was increased up to 60% and the elimination half-life was increased up to 49%. The hepatobiliary excretion substantially decreased to about 5% of the administered dose and reduced hepatic contrast signal was observed.</paragraph>
                        <paragraph>A dose adjustment is not necessary for patients with hepatic impairment.</paragraph>
                        <paragraph>In clinical studies, 489 patients had a diagnosis of liver cirrhosis (Child-Pugh category A, n = 270; category B, n = 98; category C, n = 24; unknown category, n = 97). No difference in diagnostic performance and safety was observed among these patients.</paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e1d8eff8-d204-4497-96bd-a97c786cc523">
               <id root="e836a1e3-d804-4e57-8d0a-55c37b3735d0"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10	OVERDOSAGE</title>
               <text>
                  <paragraph>The maximum dose studied in MR imaging was 0.4 mL/kg (0.1 mmol/kg) body weight and was tolerated in a manner similar to lower doses. In case of inadvertent overdosage in patients with severely impaired renal and/or hepatic function, EOVIST can be partially removed by hemodialysis<content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#ID_27fed83f-d4d1-4cb3-b841-1320ba0245a1">8.6</linkHtml>)]. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20150327"/>
            </section>
         </component>
         <component>
            <section ID="ID_b8fbd6fe-c30e-4391-a27f-ea57f88fe131">
               <id root="4342cd74-9eb3-4581-9162-053a87431e18"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION</title>
               <text>
                  <paragraph>EOVIST (gadoxetate disodium) is a paramagnetic contrast agent administered for MRI. EOVIST is provided as a sterile, clear, colorless to pale yellow aqueous solution for intravenous injection.</paragraph>
                  <paragraph>EOVIST contains the active pharmaceutical ingredient, gadoxetate disodium (GdâEOBâDTPA). The chemical name for gadoxetate disodium is (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid, gadolinium complex, disodium salt. Gadoxetate disodium has a molecular weight of 725.72 and an empirical formula of GdC<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>11</sub>Na<sub>2</sub>. The structural formula of gadoxetate disodium in aqueous solution is:</paragraph>
                  <renderMultiMedia ID="id2022349220" referencedObject="BC74A023-DCB9-4AB6-A0E6-FBD55D61AC2C"/>
                  <paragraph>Each mL of EOVIST contains 181.43 mg (0.25 mmol) of gadoxetate with 1.00 mg of caloxetate trisodium, 1.21 mg of trometamol, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection. EOVIST contains no antimicrobial preservative.</paragraph>
                  <paragraph>Pertinent physiochemical properties of EOVIST are provided in Table 2.</paragraph>
                  <table width="100%">
                     <caption>Table 2 Physicochemical Properties</caption>
                     <col width="38%"/>
                     <col width="12%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>Osmolality at 37Â°C (Osm/kg H<sub>2</sub>O)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>0.688</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Viscosity at 37Â°C (cP)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.19</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Density at 37Â°C (g/mL)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.088</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>pH</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>6.8-8</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250305"/>
               <component>
                  <observationMedia ID="BC74A023-DCB9-4AB6-A0E6-FBD55D61AC2C">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f030b69e-54bb-46bd-89dc-4809b7c4db8d">
               <id root="ed315baf-2cef-498d-83fc-e9e082373b43"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240130"/>
               <component>
                  <section ID="ID_7218af80-c793-4796-a402-4309b305b138">
                     <id root="f3a662f7-babc-4800-86d2-ed7a22f9b486"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Gadoxetate disodium is a paramagnetic compound and develops a magnetic moment when placed in a magnetic field.  The relatively large magnetic moment produced by gadoxetate disodium results in a local magnetic field, yielding enhanced relaxation rates (shortening of relaxation times) of water protons in the vicinity of the paramagnetic agent, which leads to an increase in signal intensity (brightening) of blood and tissue.</paragraph>
                        <paragraph>In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T<sub>1</sub>); and 3) differences in the spin-spin or transverse relaxation time (T<sub>2</sub>). When placed in a magnetic field, gadoxetate disodium decreases the T<sub>1</sub> and T<sub>2</sub> relaxation time in target tissue. At the recommended dose, the effect is observed with greatest sensitivity in T<sub>1</sub>-weighted MR sequences.</paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_06b01b5e-7dc7-4154-a8a1-4df89c83b5cb">
                     <id root="7009831c-0b91-4f5e-a655-449bc69f85b7"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics</title>
                     <text>
                        <paragraph>EOB-DTPA forms a stable complex with the paramagnetic gadolinium ion with a thermodynamic stability of log KGdL=â23.46. Gadoxetate disodium is a highly water-soluble, hydrophilic compound with a lipophilic moiety, the ethoxybenzyl group (EOB). Gadoxetate disodium shows a weak (&lt;10%), transient protein binding and the relaxivity in plasma is about 8.7Â L/mmol/sec at pH 7, 39Â°C and 0.47 T.</paragraph>
                        <paragraph>Gadoxetate disodium is selectively taken up by hepatocytes<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#ID_82356868-ed0d-4369-aacc-85aefb7bd6bb">12.3</linkHtml>)]</content> resulting in increased signal intensity in liver tissue <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_d278da5b-1e14-442c-9306-cdd48ecc0a19">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>EOVIST exhibits a biphasic mode of action: first, distribution in the extracellular space after injection and subsequently, selective uptake by hepatocytes (and biliary excretion) due to the lipophilic (EOB) moiety.</paragraph>
                     </text>
                     <effectiveTime value="20211231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_82356868-ed0d-4369-aacc-85aefb7bd6bb">
                     <id root="bf302476-3388-49d2-8074-1620b1f83395"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>After intravenous administration, the plasma concentration time profile of gadoxetate disodium is characterized by a bi-exponential decline.  The total distribution volume of gadoxetate disodium at steady state is about 0.21 L/kg (extracellular space); plasma protein binding is less than 10%. Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_78962487-2844-444d-b407-579a305f45b4">5.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Gadoxetate disodium is equally eliminated via the renal and hepatobiliary routes.  The mean terminal elimination half-life of gadoxetate disodium (0.01 to 0.1 mmol/kg) has been observed in healthy volunteers of 22â39 years of age to be 0.91 to 0.95 hour.  Clearance appeared to decrease slightly with increasing age.  The pharmacokinetics are dose-linear up to a dose of 0.4 mL/kg (0.1 mmol/kg), which is 4 times the recommended dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#_8.4_Pediatric_Use">8.4</linkHtml>, <linkHtml href="#ID_93997f81-d47a-4534-8b86-834337e67b66">8.5</linkHtml>, <linkHtml href="#ID_27fed83f-d4d1-4cb3-b841-1320ba0245a1">8.6</linkHtml>, </content>and<content styleCode="italics">
                              <linkHtml href="#ID_35d91d30-16f2-4827-8782-8ad3693d268f">8.7</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>A total serum clearance (Cl<sub>tot</sub>) was 250 mL/min, whereas the renal clearance (Cl<sub>r</sub>) corresponds to about 120 mL/min, a value similar to the glomerular filtration rate in healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Gadoxetate disodium is not metabolized.</paragraph>
                     </text>
                     <effectiveTime value="20240130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3cdab1b0-861c-4d3b-8618-fccb91b6a55f">
               <id root="87da17a2-0e66-4956-8f13-066afc86bd61"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250305"/>
               <component>
                  <section ID="ID_1c58610d-8223-4722-b382-516eb96978f9">
                     <id root="d9c4e381-8009-49f1-8ca5-25318bd9e126"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity studies of EOVIST have been conducted.</paragraph>
                        <paragraph>Gadoxetate disodium was not mutagenic in <content styleCode="italics">in vitro</content> reverse mutation tests in bacteria, or in chromosome aberration tests in human peripheral blood lymphocytes, and was negative in an <content styleCode="italics">in vivo</content> micronucleus test in mice after intravenous injection of doses up to 4Â mmol/kg.</paragraph>
                        <paragraph>Gadoxetate disodium had no effect on fertility and general reproductive performance of male and female rats when given in doses 6.5 times the human dose (based on body surface area).</paragraph>
                     </text>
                     <effectiveTime value="20150327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_324c584d-eb0e-48dc-b609-13454eeef7ec">
                     <id root="faaab435-834d-4d50-be44-893519e85ec2"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 	Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>A dose-related increase in QTc which was resolved by 30 minutes post dosing was observed in dogs when given a single dose of EOVIST. The increase was noted when given in doses equal to or greater than 0.1 mmol/kg (2.2 times the human dose). Maximum increase in QTcF was equal to or less than 20 ms at doses up to 0.5 mmol/kg (11 times the human dose).</paragraph>
                        <paragraph>A gait disturbance was observed in 1 of 3 mice when given EOVIST at a dose of approximately 1.1 mmol/kg (3.6 times the human dose); the disturbance occurred at 30 minutes post dosing and resolved at 4 hours post dosing.</paragraph>
                        <paragraph>Local intolerance reactions, including moderate interstitial hemorrhage, edema, and focal muscle fiber necrosis, were observed after intramuscular administration of EOVIST <content styleCode="italics">[see Warning and Precautions (5.5)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_44060f7b-c46b-43f4-b3fd-10301b22e5ea">
               <id root="fbf0ac77-2c29-4b0f-aaa6-a7d9c3ca7106"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <text>
                  <paragraph>Patients with suspected or known focal liver lesions were enrolled in two of four non-randomized, intrapatient-controlled studies that evaluated predominantly the detection (studies 1 and 2) or morphological characterization (studies 3 and 4) of liver lesions. Studies 1 and 2 ("detection" studies) enrolled patients who were scheduled for liver surgery. MRI results were compared to a reference standard that consisted of surgical histopathology and the results from intra-operative ultrasound of the liver. The studies assessed the sensitivity of pre-contrast MRI and EOVIST-contrasted MRI for the detection of liver lesions, when each set of images was compared to the reference.</paragraph>
                  <paragraph>Studies 3 and 4 ("characterization" studies) enrolled patients with known or suspected focal liver lesions, including patients who were not scheduled for liver surgery.  MRI results were compared to a reference standard that consisted of surgical histopathology and other prospectively defined criteria.  The studies assessed the correctness of liver lesion characterization by pre-contrast MRI and EOVIST-contrasted MRI, when each set of images was compared to the reference.  Lesions were characterized as one of the following choices: hepatocellular carcinoma, cholangiocarcinoma, metastasis, focal lymphoma, adenoma, focal nodular hyperplasia, hemangioma, abscess, focal liver fibrosis, regenerative nodule, focal fat, hydatid cyst, liver cyst, "not assessable", normal, no lesion or "other."</paragraph>
                  <paragraph>In all four studies, patients underwent a baseline, pre-contrast MRI followed by the administration of EOVIST at a dose of 0.025 mmol/kg, with MRI performed immediately (the "dynamic" phase) and at 10 to 20 minutes following EOVIST administration (the "hepatocyte" phase). Patients also underwent computerized tomography with contrast examinations of the liver.  Pre-contrast MRI and EOVIST-contrasted MR images were evaluated in a systematic, randomized, paired and unpaired fashion by three radiologists who were blinded to clinical information. CT images were also evaluated by the radiologists in a separate reading session.</paragraph>
                  <paragraph>Diagnostic efficacy was determined in 621 patients. The average age was 57 years (range 19 to 84 years) and 54% were male.  The ethnic representations were 90% Caucasian, 4% Black, 3% Hispanic, 2% Asian, and 1% of other ethnic groups.</paragraph>
                  <paragraph>The combination of non-contrasted and EOVIST-contrasted MR images had improved sensitivity for the detection and characterization of liver lesions, compared to pre-contrasted MR images (Tables 3 and 4). The improved sensitivity in detection of lesions was predominantly related to the detection of additional lesions among patients with multiple lesions on the pre-contrast MR images. The false positive rates for detection of lesions were similar for non-contrasted MR images and EOVIST-contrasted MR images (32% versus 34%, respectively). Liver lesion detection and characterization results were similar between CT and the combination of pre-contrasted and EOVIST-contrasted MR images.</paragraph>
                  <table cellpadding="3.5pt" width="93.72%">
                     <caption>Table 3 Sensitivity in Liver Lesion Detection</caption>
                     <col width="33%"/>
                     <col width="19%"/>
                     <col width="24%"/>
                     <col width="24%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Diagnostic Procedure</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Reader</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Study 1<br/>Sensitivity (%)<br/>n=129</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Study 2<br/>Sensitivity (%)<br/>n=126</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>Pre-contrast MRI</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>76</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>77</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>76</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>73</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>71</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>72</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>Combined pre- and EOVIST-contrast MRI</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>81</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>82</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>78</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>76</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>74</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>78</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>Difference:</paragraph>
                              <paragraph>combined pre + EOVIST-contrast MRI minus pre MRI</paragraph>
                              <paragraph>(95% confidence interval)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>5 (1, 9)*</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>5 (1, 9)*</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>2 (-1, 5)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>3 (-1, 7)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>3 (0, 6)*</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>6 (0, 10)*</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>* Statistically significant improvement</paragraph>
                  <table cellpadding="3.5pt" width="477.6pt">
                     <caption>Table 4 Proportion of Correctly Characterized Lesions</caption>
                     <col width="29%"/>
                     <col width="17%"/>
                     <col width="8%"/>
                     <col width="20%"/>
                     <col width="6%"/>
                     <col width="19%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle"/>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Study 3</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Study 4</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Diagnostic Procedure</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Reader</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">n</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Proportion correct (%) **</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">n</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Proportion correct (%) **</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>Pre-contrast MRI</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>51</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>60</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>59</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>64</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>53</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>48</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>Combined pre- and EOVIST-contrast MRI</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>67</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>61</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>76</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>76</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>58</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>177</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>67</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>Difference: combined pre- and EOVIST-contrast MRI minus<br/>pre-contrast MRI</paragraph>
                              <paragraph>(95% confidence interval)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                           <td styleCode="Rrule Lrule Toprule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 1</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>16 (7, 25)*</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>1 (-7, 10)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>Reader 2</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>17 (9, 25)*</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>11 (5, 18)*</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                              <paragraph>Reader 3</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                              <paragraph>5 (-2, 12)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule " valign="top"/>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                              <paragraph>19 (11, 27)*</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>* Statistically significant improvement</paragraph>
                  <paragraph>** Proportion of correctly characterized lesions with respect to the reference</paragraph>
               </text>
               <effectiveTime value="20150327"/>
            </section>
         </component>
         <component>
            <section ID="ID_2a904b85-f4cc-40a2-a602-6d003b88993d">
               <id root="4171aa67-82fd-412b-a37a-d7c190ec41b2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250305"/>
               <component>
                  <section ID="ID_21da6b83-7290-4292-a3d9-c41a92546305">
                     <id root="16de63a2-2004-4945-894e-eb2a238bda4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1	How Supplied</title>
                     <text>
                        <paragraph>EOVIST is supplied in single-dose, rubber stoppered containers (vials) containing 181.43 mg/mL of gadoxetate disodium (equivalent to 0.25 mmol/mL gadoxetate disodium), in the following sizes:</paragraph>
                        <paragraph>10 mL single-dose containers (vials) filled with 10 mL, boxes of 5	(NDC 50419-320-05)</paragraph>
                        <paragraph>15 mL single-dose containers (vials) filled with 15 mL, boxes of 5	(NDC 50419-320-15)</paragraph>
                     </text>
                     <effectiveTime value="20211231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3ae31e9-2991-4047-b594-c5802bf4d0d1">
                     <id root="5a752d1a-9c2c-462f-a64f-3fd5c156c881"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2	Storage and Handling</title>
                     <text>
                        <paragraph>Store at temperatures between 20Â° to 25Â° C (68Â° to 77Â° F); excursions permitted to 15Â° to 30Â° C (59Â° to 86Â°F)<content styleCode="italics"> [see USP Controlled Room Temperature]</content>.</paragraph>
                        <paragraph>EOVIST is a ready-to-use solution for single use only. Visually inspect EOVIST for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or if particulate matter is present. The rubber stopper should not be pierced more than once. Use EOVIST immediately after opening. Unused portions should be discarded. </paragraph>
                     </text>
                     <effectiveTime value="20250305"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_478eb9d1-977f-4882-acef-c55a73c7d2a0">
               <id root="0977e80a-3507-4de7-b103-99a96c0191c2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Nephrogenic Systemic Fibrosis </content>
                  </paragraph>
                  <paragraph>Instruct patients to inform their physician if they:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Have a history of kidney disease and/or liver disease</item>
                     <item>
                        <caption>â¢</caption>Have recently received a GBCA</item>
                  </list>
                  <paragraph>GBCAs increase the risk of NSF among patients with impaired elimination of drugs. To counsel patients at risk of NSF:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Describe the clinical manifestations of NSF</item>
                     <item>
                        <caption>â¢</caption>Describe procedures to screen for the detection of renal impairment</item>
                  </list>
                  <paragraph>Instruct the patients to contact their physician if they develop signs or symptoms of NSF following EOVIST administration, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle weakness.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Common Adverse Reactions </content>
                  </paragraph>
                  <paragraph>Inform patients that they may experience: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or coldness at the injection site </item>
                     <item>
                        <caption>â¢</caption>Side effects of headache, nausea, abnormal taste and feeling hot</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General Precautions </content>
                  </paragraph>
                  <paragraph>Gadolinium Retention</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Advise patients that gadolinium is retained for months or years in brain, bone, skin, and other organs in patients with normal renal function. The clinical consequences of retention are unknown. Retention depends on multiple factors and is greater following administration of linear GBCAs than following administration of macrocyclic <content styleCode="italics">GBCAs [see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_78962487-2844-444d-b407-579a305f45b4">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)].</content>
                     </item>
                  </list>
                  <paragraph>Instruct patients receiving EOVIST to inform their physician if they:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>â¢</caption>Are pregnant or breastfeeding</item>
                     <item>
                        <caption>â¢</caption>Have a history of allergic reaction to contrast media, bronchial asthma or allergic respiratory disorder</item>
                  </list>
                  <paragraph>Â© 2008, Bayer HealthCare Pharmaceuticals Inc., All rights reserved.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Bayer HealthCare Pharmaceuticals Inc.<br/>Whippany, NJ 07981 </paragraph>
                  <paragraph>Manufactured in Germany</paragraph>
               </text>
               <effectiveTime value="20240130"/>
            </section>
         </component>
         <component>
            <section ID="ID_fd3a4d49-122f-43f0-a067-4c2885295dba">
               <id root="5141c0e3-ae2f-4de9-8703-dce581f38b7d"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">EOVIST</content>
                                 <br/>
                                 <content styleCode="bold">(e-o-vist)</content>
                              </paragraph>
                              <paragraph>(gadoxetate disodium) <br/>Injection for intravenous use</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about Eovist?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>GBCAs like EOVIST may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if EOVIST is safe and effective with intrathecal use. EOVIST is not approved for this use.</item>
                                 <item>
                                    <caption>â¢</caption>Eovist contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).</item>
                                 <item>
                                    <caption>â¢</caption>It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.</item>
                                 <item>
                                    <caption>â¢</caption>Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.</item>
                                 <item>
                                    <caption>â¢</caption>At equivalent doses, the amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, Gadavist, or ProHance. </item>
                                 <item>
                                    <caption>â¢</caption>People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.</item>
                                 <item>
                                    <caption>â¢</caption>Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Eovist.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is Eovist?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>Eovist is a prescription medicine called a gadolinium-based contrast agent (GBCA).  Eovist, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner. </item>
                                 <item>
                                    <caption>â¢</caption>An MRI exam with a GBCA, including Eovist, helps your doctor to see problems better than an MRI exam without a GBCA.  Eovist is needed to better see the problems in your liver.</item>
                                 <item>
                                    <caption>â¢</caption>Your doctor has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not receive Eovist if you </content>have had a severe allergic reaction to Eovist.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before receiving Eovist, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.</item>
                                 <item>
                                    <caption>â¢</caption>are pregnant or plan to become pregnant. It is not known if Eovist can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as Eovist is received during pregnancy.</item>
                                 <item>
                                    <caption>â¢</caption>have kidney problems, diabetes, or high blood pressure.  </item>
                                 <item>
                                    <caption>â¢</caption>have had an allergic reaction to dyes (contrast agents) including GBCAs</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Eovist?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">See âWhat is the most important information I should know about Eovist?â</content>
                                 </item>
                                 <item>
                                    <caption>â¢</caption>
                                    <content styleCode="bold">Allergic reactions. Eovist can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.</content>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of Eovist include: nausea, headache, feeling hot, dizziness, and back pain.</content>
                              </paragraph>
                              <paragraph>These are not all the possible side effects of Eovist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<content styleCode="bold"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of EOVIST.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about EOVIST that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Eovist?</content>
                              </paragraph>
                              <paragraph>Active ingredient: gadoxetate disodium</paragraph>
                              <paragraph>Inactive ingredients: caloxetate trisodium, trometamol, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection.</paragraph>
                              <paragraph>Manufactured for Bayer HealthCare Pharmaceuticals Inc.</paragraph>
                              <paragraph>Manufactured in Germany</paragraph>
                              <paragraph>Â© 2008 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.</paragraph>
                              <paragraph>For more information, go to www.eovist.com or call 1-888-842-2937.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration 	3/2025</paragraph>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="ID_0c21997b-9b45-49aa-a90f-3d2c5017d0c1">
               <id root="78cd3167-1991-4538-8633-34a8b9ff7372"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Carton 5 x 10 mL </title>
               <text>
                  <paragraph>NDC 50419-320-05<br/>5 vials of 10 mL<br/>sterile solution<br/>EovistÂ® 10 mL<br/>(gadoxetate disodium)<br/>Injection<br/>0.25 mol/L<br/>Rx only<br/>Each mL contains 181.43 gadoxetate disodium and the excipients caloxetate trisodium, trometamol, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection. EovistÂ® contains no antimicrobial preservative.<br/>Single-dose container.<br/>Discard unused portion.<br/>Store at 20-25Â°C (68-77Â°F); excursions permitted to 15-30Â°C [See USP Controlled Room Temperature.] <br/>For intravenous administration.<br/>Dosage: See package insert.<br/>Mfd. for:<br/>Bayer HealthCare Pharmaceuticals Inc.<br/>Wayne, NJ 07470<br/>Mfd. in Germany<br/>
                  </paragraph>
                  <renderMultiMedia ID="id-538055332" referencedObject="ID_81ed4c0d-bea3-4682-a62e-aa10b6dc5d7d"/>
               </text>
               <effectiveTime value="20211231"/>
               <component>
                  <observationMedia ID="ID_81ed4c0d-bea3-4682-a62e-aa10b6dc5d7d">
                     <text>Eovist 10 mL carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>